pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Undisclosed
drug
save

Undisclosed

Preclinicalupdated 6mo ago
by $FATE FATE THERAPEUTICS INC
Preclinical
community read0 votes

🐶 often sniffed alongside

top 8
  • tagOncology15 co-mentions · 5 sources
  • tagPulmonology6 co-mentions · 5 sources
  • tagNSCLC5 co-mentions · 4 sources
  • tagHepatology3 co-mentions · 1 sources
  • tagPain3 co-mentions · 3 sources
  • tagOrthopedics3 co-mentions · 2 sources
  • tagNephrology3 co-mentions · 1 sources
  • tagType 2 Diabetes3 co-mentions · 2 sources

all catalysts(0)

nothing on the calendar yet

Trials studying Undisclosed

  • —Automated Quantification of Dental Plaquecompletedn=100

News(10)

  • Cellectis may cut 70% of workforce
    Follow along as BioSpace tracks job cuts and restructuring initiatives.
    biospace · 7h ago
  • PharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMO
    Less than two years after acquiring the assets, Lantheus is selling its CDMO unit and a New Jersey production plant to PharmaLogic.
    biospace · 2d ago
  • Pfizer snags $1.5B financing from PE firm Blackstone to support Metsera asset
    With 10 active or planned Phase 3 trials underway for Metsera’s berobenatide, Pfizer has signed a deal with Blackstone Life Sciences to finance the program to approval.
    biospace · 3d ago
  • Coherus cuts 30% of staffers, Gyre makes post-acquisition layoffs
    Coherus is narrowing its pipeline projects while Gyre reorganizes after an acquisition, with both biotechs conducting workforce reductions.
    biospace · 5d ago
  • Update: Compass submits psilocybin depression drug for approval after stock wobbles
    Compass Pathways has completed an FDA filing for COMP360, with an expected launch in the first half of next year. The update follows a reported regulatory submission for Usona Institute’s own psilo…
    biospace · 6d ago
  • Argenx buyout of peptide engine and Big Pharma favorite UNP could top $1B
    Unnatural Products has risen from founder Joshua Schwochert’s garage to an acquisition deal, valued at up to $1.15 billion, to join argenx.
    biospace · 6d ago
  • Spruce spins out preclinical endocrinology program into newly formed Adrenyx
    Spruce Biosciences is spinning out a preclinical endocrinology program into a newly formed subsidiary called Adrenyx Biosciences, supported with up to $50 million from an unnamed investor.
    fiercebiotech · 7d ago
  • Cash-strapped Vivoryon regains China rights to kidney disease prospect from Simcere
    Vivoryon Therapeutics has regained the China rights to its kidney disease prospect as the German biotech’s cash reserves begin to dry up.
    fiercebiotech · 11d ago
  • Boehringer bets big on China, offering $7B biobucks for Sino cancer programs
    Boehringer Ingelheim is building up its China strategy, inking a deal to develop new cancer treatments with Sino Biopharmaceutical just weeks after opening an R&D facility in Shanghai.
    biospace · 11d ago
  • Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
    Sanofi has discontinued an early-stage STAT6 degrader program licensed from Nurix Therapeutics, a decision analysts say is related to the asset itself or Sanofi’s strategic reprioritization rather…
    biospace · 11d ago
view all news mentions →
indication
Solid Tumor
phase
preclinical
Data sources
ClinicalTrials.gov
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?